231 related articles for article (PubMed ID: 18784820)
1. Immunohistochemistry for assessment of pulmonary and pleural neoplasms: a review and update.
Tan D; Zander DS
Int J Clin Exp Pathol; 2008 Jan; 1(1):19-31. PubMed ID: 18784820
[TBL] [Abstract][Full Text] [Related]
2. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
Ordóñez NG
Arch Pathol Lab Med; 2005 Nov; 129(11):1407-14. PubMed ID: 16253021
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry of pulmonary and pleural neoplasia.
Beasley MB
Arch Pathol Lab Med; 2008 Jul; 132(7):1062-72. PubMed ID: 18605762
[TBL] [Abstract][Full Text] [Related]
5. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
Ordóñez NG
Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183
[TBL] [Abstract][Full Text] [Related]
6. Review and update of uncommon primary pleural tumors: a practical approach to diagnosis.
Granville L; Laga AC; Allen TC; Dishop M; Roggli VL; Churg A; Zander DS; Cagle PT
Arch Pathol Lab Med; 2005 Nov; 129(11):1428-43. PubMed ID: 16253024
[TBL] [Abstract][Full Text] [Related]
7. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
8. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Husain AN; Colby TV; Ordóñez NG; Allen TC; Attanoos RL; Beasley MB; Butnor KJ; Chirieac LR; Churg AM; Dacic S; Galateau-Sallé F; Gibbs A; Gown AM; Krausz T; Litzky LA; Marchevsky A; Nicholson AG; Roggli VL; Sharma AK; Travis WD; Walts AE; Wick MR
Arch Pathol Lab Med; 2018 Jan; 142(1):89-108. PubMed ID: 28686500
[TBL] [Abstract][Full Text] [Related]
9. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
Marchevsky AM; LeStang N; Hiroshima K; Pelosi G; Attanoos R; Churg A; Chirieac L; Dacic S; Husain A; Khoor A; Klebe S; Lantuejoul S; Roggli V; Vignaud JM; Weynard B; Sauter J; Henderson D; Nabeshima K; Galateau-Salle F
Hum Pathol; 2017 Sep; 67():160-168. PubMed ID: 28782639
[TBL] [Abstract][Full Text] [Related]
10. Update in neoplastic lung diseases and mesothelioma.
Gordon IO; Sitterding S; Mackinnon AC; Husain AN
Arch Pathol Lab Med; 2009 Jul; 133(7):1106-15. PubMed ID: 19642737
[TBL] [Abstract][Full Text] [Related]
11. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
Brown RW; Clark GM; Tandon AK; Allred DC
Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
[TBL] [Abstract][Full Text] [Related]
12. Pleural neoplastic pathology.
Karpathiou G; Stefanou D; Froudarakis ME
Respir Med; 2015 Aug; 109(8):931-43. PubMed ID: 26048082
[TBL] [Abstract][Full Text] [Related]
13. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
14. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
Miettinen M; Sarlomo-Rikala M
Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
[TBL] [Abstract][Full Text] [Related]
15. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic efficacy of electron microscopy and pleural effusion cytology for the distinction of pleural mesothelioma and lung adenocarcinoma.
Domínguez-Malagón H; Cano-Valdez AM; González-Carrillo C; Campos-Salgado YE; Lara-Garcia A; Lopez-Mejia M; Corona-Cruz JF; Arrieta O
Ultrastruct Pathol; 2016; 40(5):254-60. PubMed ID: 27405014
[TBL] [Abstract][Full Text] [Related]
17. The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.
Alì G; Bruno R; Fontanini G
J Thorac Dis; 2018 Jan; 10(Suppl 2):S276-S284. PubMed ID: 29507796
[TBL] [Abstract][Full Text] [Related]
18. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours.
Garcia-Prats MD; Ballestin C; Sotelo T; Lopez-Encuentra A; Mayordomo JI
Histopathology; 1998 May; 32(5):462-72. PubMed ID: 9639123
[TBL] [Abstract][Full Text] [Related]
19. Sarcomatoid neoplasms of the lung and pleura.
Travis WD
Arch Pathol Lab Med; 2010 Nov; 134(11):1645-58. PubMed ID: 21043818
[TBL] [Abstract][Full Text] [Related]
20. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
Ordóñez NG
Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
